image

Key updates

What's new on Wikilite
Section Contents
  • What's new on Wikilite
    • Key updates


Date Publication Update
04/07/2019 Sidana 2019 [1215] 18.3.4. Early detection of disease relapse
20.3.3. Prognostic implications of relapse with FLCs
26/03/2019 Caillon 2019 [1214]Section 8.6.1. Comparison of absolute values
Section 8.6.4. Monitoring MM
Section 8.7. Compliance with guidelines
11/02/2019 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Systemic Light Chain Amyloidosis V.1.2019 © [1211]Section 28.3.3. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Systemic Light Chain Amyloidosis V.1.2019
Section 28.7.4. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Systemic Light Chain Amyloidosis V.1.2019
23/11/2018
Tan 2018 [1210]Section 25.9. Management of multiple myeloma in Asia: resource-stratified guidelines
23/11/2018
ASH abstracts

Section 14.2. Monoclonal sFLCs and SMM progression
Section 14.4. The prognostic value of changes in monoclonal protein concentration
Section 18.3.4. Early detection of disease relapse
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 24.4. Urine compliance
Section 28.1 AL amyloidosis introduction
Section 28.2.1 Localised amyloid disease
Section 28.8. Prognostic value of sFLC response
Section 32.3.3. sFLC and WM prognosis
Section 33.4. Prognostic value of combined FLC measurements
21/11/2018
Quock 2018 [1197]Section 28.1. Introduction to AL amyloidosis
16/11/2018
Kourelis 2018 [1196]Section 28.1. Introduction to AL amyloidosis
Jabor 2018 [1195]
Section 7.2.6 Freelite biological variation
Section 11.2.6 Hevylite biological variation
15/11/2018
Heaney 2018 [1192]Section 20.1. Introduction to multiple myeloma prognosis
Kastritis 2014 [1193]Section 20.1. Introduction to multiple myeloma prognosis
Sorrig 2017 [1194]Section 20.1. Introduction to multiple myeloma prognosis
14/11/2018
Yadav 2018 [1191]Section 15.1. Diagnosis of light chain multiple myeloma
Section 17.2. Free light chains at diagnosis
Section 20.1. Multiple myeloma prognosis: Introduction
Section 26.4. Nephrotoxicity of monoclonal FLCs
*NEW* Figure 26.2. Higher sFLC levels are associated with more severe renal impairment.
Section 27.1. Renal impairment in multiple myeloma
08/11/2018
Qiu 2018 [1189]Section 28.5.2. Patients with low amyloidogenic FLCs
Nguyen 2018 [1190]Section 28.5.2. Patients with low amyloidogenic FLCs
07/11/2018
Gavriatopoulou 2018 [1188]Section 29.2. sFLC assays support a diagnosis of LCDD
Section 29.3. Monitoring LCDD using sFLC assays
Section 34.4. POEMS syndrome
06/11/2018
Kyle 2018 [1016]Section 32.1. Introduction to Waldenström's macroglobulinaemia
Kyle 2012 [996]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Pophali 2018 [1185]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Alexanian 2003 [1186]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Kyle 2016 [1187]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
29/10/2018
Jacobs 2018 [1178]
*NEW* Section 8.4.5. Sample redilution
Section 8.6.1. Comparison of absolute values
Section 8.6.4. Monitoring MM
Lutteri 2018 [1179]
Section 8.5.2. Renal reference interval
Caponi 2018 [1184]
Section 8.6.1. Comparison of absolute values
Lutteri 2018 [1181]
Section 8.5.2. Renal reference interval
Tate 2018 [1182]
Section 8.5.2. Renal reference interval
18/10/2018
Esplin 2013 [1167]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Lee 2013 [1168]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Palladini 2018 [1169]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Lim 2018 [1170]*NEW* Chapter 28.5.1. Cardiac amyloidosis
National Amyloidosis Centre. Amyloidosis FAQ [1177]
*NEW* Chapter 28.5.1. Cardiac amyloidosis
Muchtar 2017 [1171]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Siddiqi 2017 [1172]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Gertz 2015 [1173]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Gertz 2018 [1174]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Geller 2017 [1175]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Fajardo 2018 [1176]
*NEW* Chapter 28.5.1. Cardiac amyloidosis
17/10/2018
Kumar 2018 [1162]
Section 28.1 Introduction to AL amyloidosis
17/10/2018
Scott 2018 [1166]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Radocha 2018 [1165]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Avet-Loiseau 2013 [1164]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Chng 2014 [1163]
Section 20.1. Introduction to multiple myeloma prognosis
10/10/2018
Jamil 2018 [1160]
Section 37.2.2. Freelite and Hevylite Precision on the Optilite
10/10/2018
Caillon 2018 [1159]

Section 15.2. Monitoring light chain multiple myeloma
Section 24.8. Comparison of sFLCs and urinalysis for monitoring patients
10/10/2018
Rassner 2018 [1158]
Section 7.5.2. Instruments without automated antigen excess checking
10/10/2018
Aberer 2018 [1157]
Section 35.5. Diabetes mellitus
04/10/2018
Dispenzieri 2018 [1156]
Section 34.4. POEMS syndrome
03/10/2018
Arkir 2011 [1153]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Benard 2016 [1148]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Cha 2014 [1154]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Jacobs 2018 [1065]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Laurent 2015 [1149]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
LeSourd 2009 [1150]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Ludwig 2008 [1155]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Leung 2017 [1146]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Marionneaux 2008 [1147]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
McEntee 2016 [1145]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Mirbahai 2011 [1152]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Stone 2018 [1143]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Thouless 2015 [1144]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Uner 2017 [1151]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
27/09/2018
Higgins 2018 [1138]
26.4. Nephrotoxicity of monoclonal FLCs
27/09/2018
Corre 2018 [1140]

19.1. Introduction
19.2. Clonal populations in MM
19.3. Clonal changes and clonal escape in MM
27/09/2018
Tang 2018 [1139]
18.3.5. Monitoring patients treated with mAb-based therapies
27/09/2018
Verstappen 2018 [1142]
Section 35.4.2. Primary Sjögren’s syndrome
26/09/2018
Varga 2018 [1141]
*NEW* Section 36.4. Other applications of CSF FLC measurements
24/09/2018
Kumar 2018 [1129]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Owen 2003 [1128]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Swerdlow 2017 [1127]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Buske 2018 [1126]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Kastritis 2018 [1125]

Section 32.1. Introduction to Waldenström's macroglobulinaemia
Section 32.2. IgM quantitation by routine laboratory tests
*NEW* Section 32.3.4. Guidelines for sFLC assessment in WM
20/09/2018
AACC 2018 abstracts

Section 13.1. MGUS definition and frequency
Section 23.3. Incorporation of sFLC analysis into routine screening for monoclonal gammopathies
Section 35.4.1. Systemic lupus erythematosus
20/09/2018
ISA 2018 abstracts

Section 28.1. Introduction to AL amyloidosis
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.8.1. sFLC response predicting cardiac outcomes
17/09/2018
AACC 2018 abstracts

*NEW* Section 7.3. Sample redilution
*NEW* Figure 7.4. Proportion of samples giving a final result at each dilution on the Optilite analyser.
16/08/2018
Fotiou 2018 [1104]

Section 21.1. Introduction
Section 21.4. Guideline recommendations
16/08/2018
Caers 2018 [1108]

Section 21.1. Introduction
Section 21.2. Monoclonal proteins in solitary plasmacytoma
16/08/2018 Bernardi 2013 [1100]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Saez 2017 [1099]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Leurs 2017 [1097]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Bayart 2018 [1096]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Tang 2018 [1095]
Section 12.2. Multiple myeloma and related malignant disorders
08/08/2018
AACC 2018 abstracts

Section 7.1.4. Sample and reagent stability
Section 7.4. Sample linearity
Section 7.5.3. Incidence of antigen excess
Section 7.6. Polymerisation
08/08/2018 Jülich 2018 [1089]
Section 35.4.2. Primary Sjögren’s syndrome
08/08/2018 James 2018 [1088]
Section 35.4.2. Primary Sjögren’s syndrome
08/08/2018 Sidiqi 2018 [1090]
Section 28.8. Prognostic value of sFLC response
26/07/2018 Wu 2018 [1084]
Section 14.2. Monoclonal sFLCs and SMM progression
26/07/2018 Lakshman 2018 [1083]
Section 14.2. Monoclonal sFLCs and SMM progression

Figures

References